ArticleGenes & diseases2025
Targeting METTL3 protein by proteolysis-targeting chimeras: A novel therapeutic approach for acute myeloid leukemia.
Article in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.Trends in cancer · 2026Review
- mPharmaceuticals (Basel, Switzerland) · 2026Review
- METTL3 in esophageal cancer: Current insights into molecular mechanisms, subtype heterogeneity and targeted therapy prospects (Review).International journal of oncology · 2026Review
- From METTL3 PROTACs to pyroptosis-coupled design: a medicinal chemistry agenda for next-generation targeted degraders.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Ligand-Induced Opening of a Cryptic Pocket in METTL14.ACS bio & med chem Au · 2026Article
- Emerging roles of RNA mInternational journal of oncology · 2026Review
- NNature reviews. Cancer · 2026Review
- The role of m6A RNA methyltransferase METTL3 in drug resistance mechanisms in acute myeloid leukemia.Blood research · 2026Review
- Bidirectional regulation of the ubiquitin-RNA modification axis in cancer.Frontiers in oncology · 2026Review
- KIAA1429 as a therapeutic target in osteosarcoma: challenging the linear ferroptosis pathway and evaluating translational hurdles.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Hypoxia-mediated mJournal of translational medicine · 2025Review
- Recent advances in small molecules targeting the METTL3.Future medicinal chemistry · 2025Review
- Discovery of CRBN-recruiting PROTAC degraders of the METTL3-METTL14 complex.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2025Article
- Patent landscape of small molecule inhibitors of METTL3 (2020-present).Expert opinion on therapeutic patents · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Despite numerous studies suggesting that RNA m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.